Peptide

Survodutide

Also known as

BI 456906 · BI456906 · BI-456906 · glucagon/GLP-1 dual agonist · GCGR/GLP-1R dual agonist · Zealand/Boehringer dual agonist

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Dual-receptor peptide	Survodutide, or BI 456906, targets GLP-1 and glucagon receptors and is studied as a weekly injection beneath the skin for obesity and liver disease.
Liver-fat interest	People discuss fat loss, appetite and liver-fat research. Less liver fat and less liver scarring are different outcomes; feeling energetic does not measure calories burned.

Notes

One peptide activating two hormone receptors. Survo or BI 456906 targets GLP-1 and glucagon: pathways involved in appetite, glucose and liver metabolism. Its clinical form is a weekly injection under the skin. Feeling energetic does not measure extra calories burned. Zealand Pharma — Survodutide pipeline (Official context · Accessed 2026-09-30)

Investigational status remains a material limit. Zealand describes obesity and MASH development and no marketing approval. MASH involves fatty-liver inflammation and damage; liver outcomes require clinical assessment. Zealand Pharma — Survodutide pipeline (Official context · Accessed 2026-09-30)

Survodutide is an investigational injectable peptide people discuss for fat loss, quieter appetite and liver-fat research. Some report easier eating control or more energy; others notice little change or develop fatigue and stomach trouble. Many accounts involve tirzepatide too, so they cannot isolate Survodutide's contribution.

Liver interest goes beyond the scale. A commenter considering Survo described less liver fat but worsening fibrosis on their latest scan after tirzepatide-associated weight loss. That is a reason for their interest, not a Survo outcome. Fat in the liver and scarring are different problems. Survo/Tirz stack — starting today (Community discussion · Accessed 2026-09-30)

Source context — Zealand Pharma — Survodutide pipeline: Commercial sponsor perspective; pipeline summary not independent efficacy assessment. Not a DIY dose guide. Numerical phase 3 efficacy results absent from inspected page.

Source context — Survo/Tirz stack — starting today: Overlapping posters with the January thread are not independent extra users. Many stacks, no identity testing supplied, doses/frequency incomplete in some replies. AI-generated outcome predictions in a comment are rejected, not evidence. Relative follow-up dates differ between tool views; no date inferred from them.

What people notice

Food thoughts versus hunger	One tirzepatide co-user said hunger remained but became easier to ignore after replacing cagrilintide with Survo. Other co-users still reported food noise.
Weight loss and stalls	One user reported 3–4 lb lost over a few weeks after a tirzepatide stall. Another described six months without hunger yet a two-month plateau on the combination.
Energy can become fatigue	Some report extra energy, while one 5 mg Survo/tirzepatide account describes that changing to severe fatigue.

Notes

Quieter food thoughts can coexist with hunger. A Biohacking reply describes a month after replacing cagrilintide with Survo: hunger remained, but was easier to ignore and food thoughts were less constant. Tirzepatide continued, making this a comparison within a stack rather than a Survo-only result. Survodutide suppression? (Community discussion · Accessed 2026-09-30)

Appetite suppression and food noise are not interchangeable. Fullness means getting satisfied by a smaller meal; food noise means recurring thoughts about eating. One GLP FAQ poster still reported food noise at 1.2 mg Survo with tirzepatide, then added cagrilintide and experienced nausea. The additional change cannot be credited to Survo. Tirz, Survo, AND Cagri? Anyone tried this? (Personal report · Accessed 2026-09-30) · Survodutide suppression? (Community discussion · Accessed 2026-09-30)

Extra weight loss is reported, but plateaus still happen. One Reddit user reported 3–4 lb lost over a few weeks after a tirzepatide stall. A GLP FAQ poster described six months without hunger on 3.5 mg Survo plus 7 mg tirzepatide weekly, yet also a two-month stall. Appetite and scale movement are different outcomes. Survodutide + Tirzepatide (Community discussion · Accessed 2026-09-30) · Survodutide Stackers? Thoughts? (Personal report · Accessed 2026-09-30)

Energy can turn into fatigue. One poster's early extra energy became severe fatigue at 5 mg Survo with tirzepatide. An MESO-Rx user blamed an excessive first injection for a bad experience, but gave no amount or symptoms. Survo/Tirz stack — starting today (Community discussion · Accessed 2026-09-30) · MESO-Rx giant incretin thread, page 164 (Personal report · Accessed 2026-09-30)

Source context — Survodutide suppression?: Single respondent, continued tirzepatide, Survo injection timing/amount undisclosed. Advice received by OP is not an administered dose. Relative dates inconsistent between search and open views; exact date not independently assigned. Crosspost is the same discussion, not separate corroboration.

Source context — Tirz, Survo, AND Cagri? Anyone tried this?: Multiple agents, frequency not specified for these amounts, changing treatment and prior stalls; not a pure Survo nonresponse test. Sponsored/affiliate surroundings. Congratulatory advice and safety assurances in replies are rejected. No identity/independence verification.

Source context — Survodutide + Tirzepatide: Self-selected reports, unverified products, multiple drugs and no controlled comparison. Survo repetition interval for the 2 mg report is unspecified. Opinion about receptor potency is not a verified assay. Hidden/deleted replies not credited.

Source context — Survodutide Stackers? Thoughts?: Commercial surroundings: forum explicitly allows sponsored/affiliate content and shows a peptide vendor banner. Identity, product, doses and account independence unverified. Reports of private-group responses are secondhand and not counted. Author's causal explanation about metabolism/sex/conditions is not adopted.

Source context — MESO-Rx giant incretin thread, page 164: No amount or specific adverse symptom given and no detailed Survo follow-up on this page. Most nearby energy/fatigue/onset claims concern Mazdutide or Tirzepatide and are excluded. Sponsored vendor surroundings; no verified product.

Doses people talk about

0.3 mg weekly addition	One log added 0.3 mg Survo five days after a 12.5 mg weekly tirzepatide injection and described following a trial ramp. This is an individual report.
1.2–1.5 mg weekly accounts	Separate reports describe 1.2 mg Survo weekly with tirzepatide 1.5 mg twice weekly, or up to 1.5 mg Survo weekly staggered 3–4 days after tirzepatide.
Longer combination account	One poster reported Survo 3.5 mg plus tirzepatide 7 mg, each weekly, for six months. Appetite suppression coexisted with a later stall.
Unclear-frequency reports	One account lists 2 mg Survo four days after 10 mg tirzepatide every six days, without clear Survo frequency. Another lists 5 mg Survo with 10 mg tirzepatide, frequency unstated.

Notes

0.3 mg weekly appears in an injection log. A Reddit author added 0.3 mg Survo five days after their 12.5 mg weekly tirzepatide injection, then said they were following a trial ramp. This individual report does not establish a dose to follow. Starting-log first-dose follow-up and replies (Personal report · Accessed 2026-09-30)

1.2–1.5 mg weekly reports involve other drugs. Separate posters describe 1.2 mg Survo per week with tirzepatide 1.5 mg twice weekly (3 mg weekly total), and up to 1.5 mg Survo per week staggered 3–4 days after tirzepatide. Neither describes a clean Survo-only trial. Survodutide + Tirzepatide (Community discussion · Accessed 2026-09-30)

Page 1, July 14 2025 post #8 by Drew_19: 3.5 mg/week Survo, 7 mg/week tirzepatide, six months without hunger and two-month plateau. Thread opening and adjoining posts read. Survodutide Stackers? Thoughts? (Personal report · Accessed 2026-09-30)

Other amounts use different schedules. One report lists 2 mg Survo four days after 10 mg tirzepatide taken every six days; Survo frequency is unclear. Another lists 5 mg Survo with 10 mg tirzepatide, frequency unstated. These are not interchangeable weekly totals. Survodutide + Tirzepatide (Community discussion · Accessed 2026-09-30) · Survo/Tirz stack — starting today (Community discussion · Accessed 2026-09-30)

Source context — Starting-log first-dose follow-up and replies: Same thread as start; not an independent cohort. Follow-up subjective and on tirzepatide. Full nested chart not independently opened; exact chart values not reproduced.

Half-life, onset & duration

Felt onset	One 0.3 mg first injection brought no major change, then a slight appetite/food-noise difference the author said might be placebo. A dependable hour-by-hour onset is unknown.
Felt duration	Weekend appetite coverage was reported with tirzepatide, without disclosed Survo injection timing. Another user describes next-day fatigue lasting about a day; neither establishes standalone benefit duration.
Half-life	Human phase 1 research reported more than 100 hours after SubQ dosing. The separate 'approximately one week' community summary lacks a direct PK citation and is not an appetite-duration measurement.

Notes

The first 0.3 mg did not bring a dramatic change. The starting-log author described no major positives or negatives after the first injection, then a slight appetite and food-noise change that they themselves said might be placebo. There is no reliable hour-by-hour onset in that account. Starting-log first-dose follow-up and replies (Personal report · Accessed 2026-09-30)

Late-week appetite coverage is described within stacks. One Biohacking reply says Survo carried appetite control through the weekend when tirzepatide seemed to fade around day five. Timing of the Survo injection was not disclosed, so this does not establish a standalone single-dose duration. Survodutide suppression? (Community discussion · Accessed 2026-09-30)

Next-day sleepiness lasted about a day in one account. Another poster described afternoon fatigue the day after injections, with that recurring pattern taking months to settle. A one-day symptom window and months of adaptation are different clocks; neither predicts another person's experience. Survo/Tirz stack — starting today (Community discussion · Accessed 2026-09-30)

Human phase 1 half-life was more than 100 hours. Jungnik and colleagues reported this after subcutaneous dosing in single-dose and initial repeated-dose cohorts. That supports long exposure; it does not validate the community's exact one-week estimate or identify when hunger returns. Jungnik et al. — Phase I studies of BI 456906 (Official context · Accessed 2026-09-30)

“Approximately one week” is a circulated summary claim. A PeptideSelect overview repeats this number without a direct pharmacokinetic citation beside it. It summarizes supposed research; it is not a measurement by the poster. Half-life means blood concentration falling by half, not appetite control lasting exactly seven days. What Studies Show About Survodutide (Community guide · Accessed 2026-09-30)

Source context — Jungnik et al. — Phase I studies of BI 456906: Sponsor-funded early human trial, small cohorts and short follow-up; not community measurement or real-world stack safety. Supplementary tables not independently inspected. Rodent efficacy mentioned in introduction is not credited as a human benefit.

Source context — What Studies Show About Survodutide: No direct PK citation beside the estimate; mixes speculative or overconfident claims with research language. No firsthand timing measurement. Reconstitution recipe, presumed safety, superiority and precise clinical ladder are excluded. Promotional-sounding prose; authorship/commercial connection unverified.

Cycles people discuss

Weeks to months	Accounts range from a few weeks to several months of co-use, sometimes with a plan to return to tirzepatide alone near goal weight. No settled on/off cycle follows.
Stopping and reset claims	One blinded trial participant felt unchanged after stopping, with assignment still unknown. Forum breaks to 'reset tolerance' are disputed and do not establish a Survo restart interval.

Notes

Accounts span a few weeks to several months. One user had only a few weeks' supply. Another described co-use from March to July and planned a return to tirzepatide alone near goal weight. Neither establishes an on/off cycle. Survodutide + Tirzepatide (Community discussion · Accessed 2026-09-30) · Survo/Tirz stack — starting today (Community discussion · Accessed 2026-09-30)

Stopping can feel unchanged despite earlier weight loss. A SYNCHRONIZE-1 participant reported 231 to 179 lb, later fluctuating around 180–185 lb, with a final June injection and no felt difference afterward. Their blinded assignment stayed unknown. The account cannot establish durability or a restart schedule. SYNCHRONIZE-1 participant and same-author follow-up (Personal report · Accessed 2026-09-30)

Breaks to “reset tolerance” are disputed. One poster suggested a tirzepatide break; another feared losing the prior benefit. This class discussion does not demonstrate a Survodutide reset interval. Survo/Tirz stack — starting today (Community discussion · Accessed 2026-09-30)

Source context — SYNCHRONIZE-1 participant and same-author follow-up: Blinded assignment unconfirmed; no records independently verified. Thread creation date 2023-12-14 is not the date of participant comments. Prior frozen detail dates comments February 2024 and September 2025; current body showed relative dates only, so article does not independently reassert them.

Stacks

Tirzepatide	Much of the practical discussion is Survo/tirzepatide co-use. Overlapping three receptor targets does not make two drugs equivalent to retatrutide.
Cagrilintide addition	One user with food noise despite Survo/tirzepatide added cagrilintide and experienced nausea. The additional appetite change cannot be assigned to Survo alone.
Food and training habits	Protein, resistance training, smaller meals and hydration recur in class discussion. These habits do not prove prevention of lean-mass loss or Survo-related problems.

Notes

A Survo–tirzepatide combination is not Retatrutide. People compare the combination with Reta because it overlaps three receptor targets. The Reddit discussion disputes that equivalence: two drugs have different exposures and receptor activity from one triple agonist. Survodutide + Tirzepatide (Community discussion · Accessed 2026-09-30)

Meal comfort matters alongside weight targets. A maintenance poster described enjoying appropriately sized meals after reducing their tirzepatide exposure and using 1.2 mg Survo weekly. Older reports also discuss protein, resistance training, smaller meals and hydration as incretin-class habits; they do not demonstrate prevention of Survo-related problems or lean-mass loss. Survodutide + Tirzepatide (Community discussion · Accessed 2026-09-30)

Watch for

Stomach symptoms and fatigue	Reports include reflux, sulfur burps, constipation, nausea and fatigue, sometimes after increases. A tolerable account does not establish combination safety.
Slow or uncertain response	A blinded participant reported about 1 lb lost monthly despite later symptoms. Believing they received active drug did not confirm their assignment.
Investigational products	The saved development record describes an investigational drug without marketing approval. Unofficial vial labels do not verify identity, potency or sterility.

Notes

Reflux, burping, constipation and nausea appear in reports. These occur in the co-use discussion, including mild nausea and sulfur burps for about a day after dose increases. Stomach intolerance also appears in human research. A tolerable experience in one poster does not establish stack safety. Survodutide + Tirzepatide (Community discussion · Accessed 2026-09-30) · Jungnik et al. — Phase I studies of BI 456906 (Official context · Accessed 2026-09-30)

Little weight loss can persist despite symptoms. A blinded participant reported about 1 lb lost each month after starting in February, with reduced hunger, constipation, headaches and nausea-related sensations developing later. Believing they received active drug did not confirm their assignment. I'm not responding (Personal report · Accessed 2026-09-30)

The vial label does not verify the exposure. Trial supply and unofficial research vials are different evidence settings. A label alone establishes neither identity, potency nor sterility; no independent product results were supplied in these accounts.

Source context — I'm not responding: Assignment unknown; subjective signs do not establish active treatment. Lifestyle changed, no verified weight records. A reply's large loss on a stack and speculation about placebo are not promoted to diagnosis.

Full notes

What Survodutide is

One peptide activating two hormone receptors. Survo or BI 456906 targets GLP-1 and glucagon: pathways involved in appetite, glucose and liver metabolism. Its clinical form is a weekly injection under the skin. Feeling energetic does not measure extra calories burned. Official context
A Survo–tirzepatide combination is not Retatrutide. People compare the combination with Reta because it overlaps three receptor targets. The Reddit discussion disputes that equivalence: two drugs have different exposures and receptor activity from one triple agonist. Reddit · r/survodutide

Benefits people seek and report

Quieter food thoughts can coexist with hunger. A Biohacking reply describes a month after replacing cagrilintide with Survo: hunger remained, but was easier to ignore and food thoughts were less constant. Tirzepatide continued, making this a comparison within a stack rather than a Survo-only result. Reddit · r/Biohacking
Extra weight loss is reported, but plateaus still happen. One Reddit user reported 3–4 lb lost over a few weeks after a tirzepatide stall. A GLP FAQ poster described six months without hunger on 3.5 mg Survo plus 7 mg tirzepatide weekly, yet also a two-month stall. Appetite and scale movement are different outcomes. Reddit · r/survodutide Personal report
Liver interest goes beyond the scale. A commenter considering Survo described less liver fat but worsening fibrosis on their latest scan after tirzepatide-associated weight loss. That is a reason for their interest, not a Survo outcome. Fat in the liver and scarring are different problems. Reddit · r/survodutide

Doses people discuss

0.3 mg weekly appears in an injection log. A Reddit author added 0.3 mg Survo five days after their 12.5 mg weekly tirzepatide injection, then said they were following a trial ramp. This individual report does not establish a dose to follow. Personal report
1.2–1.5 mg weekly reports involve other drugs. Separate posters describe 1.2 mg Survo per week with tirzepatide 1.5 mg twice weekly (3 mg weekly total), and up to 1.5 mg Survo per week staggered 3–4 days after tirzepatide. Neither describes a clean Survo-only trial. Reddit · r/survodutide
Other amounts use different schedules. One report lists 2 mg Survo four days after 10 mg tirzepatide taken every six days; Survo frequency is unclear. Another lists 5 mg Survo with 10 mg tirzepatide, frequency unstated. These are not interchangeable weekly totals. Reddit · r/survodutide Reddit · r/survodutide

Half-life claims

“Approximately one week” is a circulated summary claim. A PeptideSelect overview repeats this number without a direct pharmacokinetic citation beside it. It summarizes supposed research; it is not a measurement by the poster. Half-life means blood concentration falling by half, not appetite control lasting exactly seven days. Community guide
The reports do not establish a personal clearance time. Late-week appetite effects describe sensations, not a blood half-life, washout time or safe overlap interval. Reddit · r/Biohacking

When changes are noticed

The first 0.3 mg did not bring a dramatic change. The starting-log author described no major positives or negatives after the first injection, then a slight appetite and food-noise change that they themselves said might be placebo. There is no reliable hour-by-hour onset in that account. Personal report
Little weight loss can persist despite symptoms. A blinded participant reported about 1 lb lost each month after starting in February, with reduced hunger, constipation, headaches and nausea-related sensations developing later. Believing they received active drug did not confirm their assignment. Personal report

How long reported effects last

Late-week appetite coverage is described within stacks. One Biohacking reply says Survo carried appetite control through the weekend when tirzepatide seemed to fade around day five. Timing of the Survo injection was not disclosed, so this does not establish a standalone single-dose duration. Reddit · r/Biohacking
Next-day sleepiness lasted about a day in one account. Another poster described afternoon fatigue the day after injections, with that recurring pattern taking months to settle. A one-day symptom window and months of adaptation are different clocks; neither predicts another person's experience. Reddit · r/survodutide

Courses, maintenance and stopping

Accounts span a few weeks to several months. One user had only a few weeks' supply. Another described co-use from March to July and planned a return to tirzepatide alone near goal weight. Neither establishes an on/off cycle. Reddit · r/survodutide Reddit · r/survodutide
Stopping can feel unchanged despite earlier weight loss. A SYNCHRONIZE-1 participant reported 231 to 179 lb, later fluctuating around 180–185 lb, with a final June injection and no felt difference afterward. Their blinded assignment stayed unknown. The account cannot establish durability or a restart schedule. Personal report
Breaks to “reset tolerance” are disputed. One poster suggested a tirzepatide break; another feared losing the prior benefit. This class discussion does not demonstrate a Survodutide reset interval. Reddit · r/survodutide

What to watch for

Energy can turn into fatigue. One poster's early extra energy became severe fatigue at 5 mg Survo with tirzepatide. An MESO-Rx user blamed an excessive first injection for a bad experience, but gave no amount or symptoms. Reddit · r/survodutide Personal report
Reflux, burping, constipation and nausea appear in reports. These occur in the co-use discussion, including mild nausea and sulfur burps for about a day after dose increases. Stomach intolerance also appears in human research. A tolerable experience in one poster does not establish stack safety. Reddit · r/survodutide Official context
The vial label does not verify the exposure. Trial supply and unofficial research vials are different evidence settings. A label alone establishes neither identity, potency nor sterility; no independent product results were supplied in these accounts. Community

Separately measured research context

Human phase 1 half-life was more than 100 hours. Jungnik and colleagues reported this after subcutaneous dosing in single-dose and initial repeated-dose cohorts. That supports long exposure; it does not validate the community's exact one-week estimate or identify when hunger returns. Official context
Investigational status remains a material limit. Zealand describes obesity and MASH development and no marketing approval. MASH involves fatty-liver inflammation and damage; liver outcomes require clinical assessment. Official context

What the community comparisons add

Appetite suppression and food noise are not interchangeable. Fullness means getting satisfied by a smaller meal; food noise means recurring thoughts about eating. One GLP FAQ poster still reported food noise at 1.2 mg Survo with tirzepatide, then added cagrilintide and experienced nausea. The additional change cannot be credited to Survo. Personal report Reddit · r/Biohacking
Meal comfort matters alongside weight targets. A maintenance poster described enjoying appropriately sized meals after reducing their tirzepatide exposure and using 1.2 mg Survo weekly. Older reports also discuss protein, resistance training, smaller meals and hydration as incretin-class habits; they do not demonstrate prevention of Survo-related problems or lean-mass loss. Reddit · r/survodutide Community